Anixa Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Millions USD. Fiscal year is Nov - Oct.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Oct '25 Oct 31, 2025	Oct '24 Oct 31, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021
Net Income	-10.93	-12.55	-9.81	-13.6	-12.95
Depreciation & Amortization	0.04	0.04	0.05	0.04	0.06
Loss (Gain) From Sale of Assets	-	-	-	-	-0.01
Loss (Gain) From Sale of Investments	-0.14	-	-	-	-
Stock-Based Compensation	3.81	4.8	4.74	6.75	8.06
Other Operating Activities	-0.1	-0.14	-0.12	-0.18	-0.17
Change in Accounts Receivable	0.17	0.1	-0.22	-0.03	-
Change in Accounts Payable	-0.36	0.32	-0.06	0.13	-0.1
Change in Other Net Operating Assets	0.34	0.11	-0.78	0.39	0.17
Operating Cash Flow	-7.17	-7.34	-6.21	-6.49	-4.94
Sale of Property, Plant & Equipment	-	-	-	-	0.04
Investment in Securities	4.87	4.28	-5.6	-10.73	-3.96
Investing Cash Flow	4.87	4.28	-5.6	-10.73	-3.92
Issuance of Common Stock	2.39	3.42	0.37	0.45	31.57
Repurchase of Common Stock	-	-0.01	-	-	-
Other Financing Activities	-0.11	-	-	-	-
Financing Cash Flow	2.28	3.42	0.37	0.45	31.57
Net Cash Flow	-0.03	0.36	-11.45	-16.77	22.71
Free Cash Flow	-7.17	-7.34	-6.21	-6.49	-4.94
Free Cash Flow Margin	-	-	-2956.67%	-	-964.45%
Free Cash Flow Per Share	-0.22	-0.23	-0.20	-0.21	-0.17
Levered Free Cash Flow	-3.29	-3	-3.02	-1.26	0.04
Unlevered Free Cash Flow	-3.29	-3	-3.02	-1.26	0.04
Change in Working Capital	0.15	0.53	-1.06	0.49	0.08

Source: S&P Global Market Intelligence. Standard template. Financial Sources.